Related references
Note: Only part of the references are listed.In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus
A. J. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
The Lord of the Rings: Structure and Mechanism of the Sliding Clamp Loader
Brian A. Kelch
BIOPOLYMERS (2016)
Primase is required for helicase activity and helicase alters the specificity of primase in the enteropathogen Clostridium difficile
Erika van Eijk et al.
OPEN BIOLOGY (2016)
Clostridium difficile infection
Wiep Klaas Smits et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Kibdelomycin Is a Bactericidal Broad-Spectrum Aerobic Antibacterial Agent
Sheo B. Singh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Targeting DnaN for tuberculosis therapy using novel griselimycins
Angela Kling et al.
SCIENCE (2015)
SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model
S. D. Baines et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
In Silico Screening for Novel Inhibitors of DNA Polymerase III Alpha Subunit of Mycobacterium tuberculosis (MtbDnaE2, H37Rv)
Alka Jadaun et al.
PLOS ONE (2015)
Structures of Kibdelomycin Bound to Staphylococcus aureus GyrB and ParE Showed a Novel U-Shaped Binding Mode
Jun Lu et al.
ACS CHEMICAL BIOLOGY (2014)
Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence
Ellie J. C. Goldstein et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
In Vivo Assessment of SMT19969 in a Hamster Model of Clostridium difficile Infection
William Weiss et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Kibdelomycin Is a Potent and Selective Agent against Toxigenic Clostridium difficile
Lynn Miesel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
NBTI 5463 Is a Novel Bacterial Type II Topoisomerase Inhibitor with Activity against Gram-negative Bacteria and In Vivo Efficacy
Thomas J. Dougherty et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Mechanism of Quinolone Action and Resistance
Katie J. Aldred et al.
BIOCHEMISTRY (2014)
Emerging insights on intestinal dysbiosis during bacterial infections
Tu Anh N. Pham et al.
CURRENT OPINION IN MICROBIOLOGY (2014)
Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase
David E. Ehmann et al.
CURRENT OPINION IN PHARMACOLOGY (2014)
Prospects for new antibiotics: a molecule-centered perspective
Christopher T. Walsh et al.
JOURNAL OF ANTIBIOTICS (2014)
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
Alimuddin I. Zumla et al.
LANCET INFECTIOUS DISEASES (2014)
Comprehensive analysis of DNA polymerase III α subunits and their homologs in bacterial genomes
Kestutis Timinskas et al.
NUCLEIC ACIDS RESEARCH (2014)
Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success
Liam S. Redgrave et al.
TRENDS IN MICROBIOLOGY (2014)
Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection
Casey M. Theriot et al.
NATURE COMMUNICATIONS (2014)
MBX-500 Is Effective for Treatment of Clostridium difficile Infection in Gnotobiotic Piglets
Jennifer Steele et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Advances in Rational Drug Design
M. Rami Reddy
CURRENT PHARMACEUTICAL DESIGN (2013)
Emergence and global spread of epidemic healthcare-associated Clostridium difficile
Miao He et al.
NATURE GENETICS (2013)
Protein Interactions in Genome Maintenance as Novel Antibacterial Targets
Aimee H. Marceau et al.
PLOS ONE (2013)
Replication Clamps and Clamp Loaders
Mark Hedglin et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
A Novel Agent Effective against Clostridium difficile Infection
Sofya Dvoskin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
MBX-500, a Hybrid Antibiotic with In Vitro and In Vivo Efficacy against Toxigenic Clostridium difficile
Michelle M. Butler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
The kinetic mechanism of S. pneumoniae DNA ligase and inhibition by adenosine-based antibacterial compounds
Hans Jahic et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Discovery of bacterial NAD+-dependent DNA ligase inhibitors: Improvements in clearance of adenosine series
Suzanne S. Stokes et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity
Jean-Philippe Surivet et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Architecture and Conservation of the Bacterial DNA Replication Machinery, an Underexploited Drug Target
Andrew Robinson et al.
CURRENT DRUG TARGETS (2012)
Bacterial DNA replication enzymes as targets for antibacterial drug discovery
Gautam Sanyal et al.
EXPERT OPINION ON DRUG DISCOVERY (2012)
Antimicrobial Use and Risk for Recurrent Clostridium difficile Infection
Dimitri M. Drekonja et al.
AMERICAN JOURNAL OF MEDICINE (2011)
Novel Bacterial NAD+-Dependent DNA Ligase Inhibitors with Broad-Spectrum Activity and Antibacterial Efficacy In Vivo
Scott D. Mills et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Exploiting bacterial DNA gyrase as a drug target: current state and perspectives
Frederic Collin et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2011)
Discovery of bacterial NAD+-dependent DNA ligase inhibitors: Optimization of antibacterial activity
Suzanne S. Stokes et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
7-Alkyl-N2-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity
Wei-chu Xu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Discovery of Kibdelomycin, A Potent New Class of Bacterial Type II Topoisomerase Inhibitor by Chemical-Genetic Profiling in Staphylococcus aureus
John W. Phillips et al.
CHEMISTRY & BIOLOGY (2011)
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Thomas J. Louie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon
Mary C. Rea et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
N-Benzyl-3-sulfonamidopyrrolidines Are a New Class of Bacterial DNA Gyrase Inhibitors
Marie H. Foss et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
In front of and behind the replication fork: bacterial type IIA topoisomerases
Claudia Sissi et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2010)
Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance
Varvara Pokrovskaya et al.
EXPERT OPINION ON DRUG DISCOVERY (2010)
New quinolone antibiotics: a survey of the literature from 2005 to 2010
Jason A. Wiles et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
Type IIA topoisomerase inhibition by a new class of antibacterial agents
Benjamin D. Bax et al.
NATURE (2010)
Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance
Alexandre Wohlkonig et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin
Gerald W. Tannock et al.
MICROBIOLOGY-SGM (2010)
Small-molecule tools for dissecting the roles of SSB/protein interactions in genome maintenance
Duo Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Quinazolin-2-ylamino-quinazolin-4-ols as novel non-nucleoside inhibitors of bacterial DNA polymerase III
Joseph Guiles et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Quinolones: Action and Resistance Updated
Karl Drlica et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2009)
Discovery and design of DNA and RNA ligase inhibitors in infectious microorganisms
Robert V. Swift et al.
EXPERT OPINION ON DRUG DISCOVERY (2009)
DNA Ligases: Progress and Prospects
Stewart Shuman
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Targeting the Replication Initiator of the Second Vibrio Chromosome: Towards Generation of Vibrionaceae-Specific Antimicrobial Agents
Yoshiharu Yamaichi et al.
PLOS PATHOGENS (2009)
Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases
Michael T. Black et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
New DNA Polymerase IIIC Inhibitors: 3-Subtituted Anilinouracils with Potent Antibacterial Activity in vitro and in vivo
Niels Svenstrup et al.
CHEMMEDCHEM (2008)
SSB as an Organizer/Mobilizer of Genome Maintenance Complexes
Robert D. Shereda et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2008)
A robust screen for novel antibiotics: specific knockout of the initiator of bacterial DNA replication
Solveig Fossum et al.
FEMS MICROBIOLOGY LETTERS (2008)
Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea
Ju Young Chang et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe
Patrizia Spigaglia et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2008)
Network pharmacology: the next paradigm in drug discovery
Andrew L. Hopkins
NATURE CHEMICAL BIOLOGY (2008)
Evaluation of NAD+-dependent DNA ligase of mycobacteria as a potential target for antibiotics
Malgorzata Korycka-Machala et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Novel pyrazole derivatives as potent inhibitors of type II topoisomerases.: Part 1:: Synthesis and preliminary SAR analysis
Laurent Gomez et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound
Michelle M. Butler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Triaminotriazine DNA helicase inhibitors with antibacterial activity
GA McKay et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Ecological and evolutionary forces shaping microbial diversity in the human intestine
RE Ley et al.
CELL (2006)
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors
CX Zhi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Novel non-nucleobase inhibitors of Staphylococcus aureus DNA polymerase IIIC
Y Rose et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
An epidemic, toxin gene-variant strain of Clostridium difficile
LC McDonald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Synthesis and antibacterial activity of 3-substituted-6-(3-ethyl-4-methylanilino)uracils
CX Zhi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Mechanisms of resistance to quinolones
GA Jacoby
CLINICAL INFECTIOUS DISEASES (2005)
Discovery of antagonist peptides against bacterial helicase-primase interaction in B-stearothermophilus by reverse yeast three-hybrid
L Gardiner et al.
CHEMISTRY & BIOLOGY (2005)
Biological characterization of novel inhibitors of the gram-positive DNA polymerase IIIC enzyme
A Kuhl et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Active site directed inhibitors of replication-specific bacterial DNA polymerases
GE Wright et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
DNA minor groove binders as potential antitumor and antimicrobial agents
PG Baraldi et al.
MEDICINAL RESEARCH REVIEWS (2004)
Synthesis of substituted 6-anilinouracils and their inhibition of DNA polymerase IIIC and gram-positive bacterial growth
CX Zhi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection
J Ruiz
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Low frequencies of resistance among Staphylococcus and Enterococcus species to the bactericidal DNA polymerase inhibitor N3-hydroxybutyl 6-(3′-ethyl-4′-methylanilino) uracil
MM Butler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Functional characterisation of mycobacterial DNA gyrase: an efficient decatenase
UH Manjunatha et al.
NUCLEIC ACIDS RESEARCH (2002)
Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition
M Takei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Topoisomerase IV, alone, unknots DNA in E-coli
RW Deibler et al.
GENES & DEVELOPMENT (2001)
Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus:: Different patterns of quinolone-induced inhibition of DNA synthesis
B Fournier et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
In vitro antimicrobial activities of novel anilinouracils which selectively inhibit DNA polymerase III of gram-positive bacteria
JS Daly et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
